Prevention of hepatitis E: Another step forward

Future Microbiology

Volumn 6, Issue 1, 2011, Pages 23-27

  Goel, Amit ^a   Aggarwal, Rakesh ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

hepatitis E; randomized controlled trial; vaccine

Indexed keywords

HEPATITIS E VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VACCINATION; VIRUS CAPSID;

ESCHERICHIA COLI; HEPATITIS E VIRUS; HEXAPODA; MIRIDAE;

EID: 78650469265     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.151     Document Type: Article

References (21)

1. Zhu F-C, Zhang J, Zhang X-F et al.: Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, Phase 3 trial. Lancet 376, 895-902 (2010).
2. Kamar N, Selves J, Mansuy JM et al.: Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N. Engl. J. Med. 358, 811-817 (2008).
3. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S: Persistent carriage of hepatitis E virus in patients with HIV infection. N. Engl. J. Med. 361, 1025-1027 (2009).
4. Ollier L, Tieulie N, Sanderson F et al.: Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann. Intern. Med. 150, 430-431 (2009).
5. Tam AW, Smith MM, Guerra ME et al.: Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185, 120-131 (1991).
6. Lu L, Li C, Hagedorn CH: Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev. Med. Virol. 16, 5-36 (2006).
7. Aggarwal R, Naik S: Epidemiology of hepatitis E: current status. J. Gastroenterol. Hepatol. 24, 1484-1493 (2009).
8. Vishwanathan R: Infectious hepatitis in Delhi (1955-1956): a critical study: epidemiology. Indian J. Med. Res. 45(Suppl. 1), 1-29 (1957).
9. Mansuy JM, Abravanel F, Miedouge M et al.: Acute hepatitis E in south-west France over a 5-year period. J. Clin. Virol. 44, 74-77 (2009).
10. Dalton HR, Thurairajah PH, Fellows HJ et al.: Autochthonous hepatitis E in southwest England. J. Viral Hepat. 14, 304-309 (2007).
11. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI: Incidence and severity of viral hepatitis in pregnancy. Am. J. Med. 70, 252-255 (1981).
12. Kumar A, Aggarwal R, Naik SR, Saraswat V, Ghoshal UC, Naik S.: Hepatitis E virus is responsible for decompensation of chronic liver disease in an endemic region. Indian J. Gastroenterol. 23, 59-62 (2004).
13. Tam A, White R, Yarbough PO et al.: In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes. Virology 238, 94-102 (1997).
14. Aggarwal R, Shahid J: Hepatitis E vaccine. Hepatol. Int. 2, 308-315 (2008).
15. Purdy MA, McCaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley DW: Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J. Med. Virol. 41, 90-94 (1993).
16. Tsarev SA, Tsareva TS, Emerson SU et al.: Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc. Natl Acad. Sci. USA 91, 10198-10202 (1994).
17. Tsarev SA, Tsareva TS, Emerson SU et al.: Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 15, 1834-1838 (1997).
18. Purcell RH, Nguyen H, Shapiro M et al.: Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 21, 2607-2615 (2003).
19. Shrestha MP, Scott RM, Joshi DM et al.: Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 356, 895-903 (2007).
20. Li SW, Zhang J, Li YM et al.: A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 23, 2893-2901 (2005).
21. Zhang J, Liu CB, Li RC et al.: Randomized-controlled Phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 27, 1869-1874 (2009).